<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307656</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-517</org_study_id>
    <nct_id>NCT02307656</nct_id>
  </id_info>
  <brief_title>Taste Properties of Atazanavir and Cobicistat</brief_title>
  <official_title>Assessment of the Taste Properties of Atazanavir and Cobicistat and Pediatric Oral Test Formulations Containing Both Atazanavir and Cobicistat in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the taste properties of atazanavir (ATV) and cobicistat
      (COBI) alone and in combination as well as oral test formulations containing both ATV and
      COBI.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2014</start_date>
  <completion_date type="Anticipated">April 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taste properties of ATV &amp; COBI alone &amp; in combination as well as oral test formulations containing both ATV &amp; COBI Aromatic identity will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Every 6 weeks from the time of subject enrollment up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of ATV &amp; COBI alone &amp; in combination as well as oral test formulations containing both ATV &amp; COBI amplitude will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Every 6 weeks from the time of subject enrollment up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of ATV &amp; COBI alone &amp; in combination as well as oral test formulations containing both ATV &amp; COBI mouth-feel will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Every 6 weeks from the time of subject enrollment up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of ATV &amp; COBI alone &amp; in combination as well as oral test formulations containing both ATV &amp; COBI off-notes will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Every 6 weeks from the time of subject enrollment up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of ATV &amp; COBI alone &amp; in combination as well as oral test formulations containing both ATV &amp; COBI aftertaste will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Every 6 weeks from the time of subject enrollment up to 2 years</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Incident of adverse events will be tabulated and reviewed for potential significance and clinical important</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>HIV in Adults</condition>
  <arm_group>
    <arm_group_label>Atazanavir and Cobicistat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)
Stage 2:Taste Optimization using API (flavours and sweeteners)
Stage 3:Prototypes of the API - containing clinical trial materials</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <arm_group_label>Atazanavir and Cobicistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <arm_group_label>Atazanavir and Cobicistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Pharmaceutical Ingredient</intervention_name>
    <arm_group_label>Atazanavir and Cobicistat</arm_group_label>
    <other_name>(API)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Men and women, ages ≥18 years

          -  Subjects who are qualified professional sensory panelists

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history and physical assessment

        Exclusion Criteria:

          -  Any acute or chronic condition that may alter taste or smell sensory perception

          -  Any significant acute or chronic medical illness or any surgery within 4 weeks of the
             study drug administration

          -  Positive HIV test using an oral swab kit (such as OraQuick®) to detect HIV-1 or -2
             antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Senopsys Llc</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

